Concepedia

Ruzanna Atoyan

RA

Statistics

Publications

16

Citations

1.4K

H-Index

15

Active since

2003

Affiliations

Boston University(Current)

Curis (United States)

University of Bradford

Harvard University

Ruzanna Atoyan is an author at Boston University specializing in medicine, oncology, and molecular oncology.

Publications per year

2003–2018

16

Publications

16

Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling

Changgeng Qian, Cheng-Jung Lai, Rudi Bao et al. · Clinical Cancer Research · 2012 · 241 citations

Medicine, Oncology, Pharmacology +15

CUDC-101, a Multitargeted Inhibitor of Histone Deacetylase, Epidermal Growth Factor Receptor, and Human Epidermal Growth Factor Receptor 2, Exerts Potent Anticancer Activity

Cheng-Jung Lai, Rudi Bao, Xu Tao et al. · Cancer Research · 2010 · 212 citations · Full text

Medicine, Oncology, Pharmacology +17

Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers

Kaiming Sun, Ruzanna Atoyan, Mylissa Borek et al. · Molecular Cancer Therapeutics · 2016 · 147 citations

Medicine, Cancer Biology, Oncology +16

CUDC-305, a Novel Synthetic HSP90 Inhibitor with Unique Pharmacologic Properties for Cancer Therapy

Rudi Bao, Cheng-Jung Lai, Hui Qu et al. · Clinical Cancer Research · 2009 · 112 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +10

A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma

Thomas J. Galloway, Lori J. Wirth, A. D. Colevas et al. · Clinical Cancer Research · 2015 · 99 citations · Full text

Medicine, Oncology, Pharmacology +16

1–5 of 16